LAKE FOREST, Ill., Oct. 7 /PRNewswire-FirstCall/ -- Hospira (NYSE:
HSP), a leading global specialty pharmaceutical and medication
delivery company, today announced that the new national infusion
pump and solutions and equipment agreements with Novation became
effective Oct. 1, 2010. Novation is
the leading healthcare supply contracting company of VHA Inc. and
the University HealthSystem Consortium (UHC) and Provista. The
contracts provide the members served by Novation with continued
access to Hospira infusion pumps, related sets and disposable
devices, along with intravenous (I.V.) solutions, nutritionals and
drug delivery products. These awards provide Hospira contract
access for the first time to the 300 UHC member hospitals. The new
agreements are effective for five years.
"The comprehensive nature of Hospira's portfolio provides
flexibility to support the diverse needs of the members served by
Novation," said Pete Baker, vice
president and general manager, Commercial Service Operations,
Hospira. "With many hospitals today focused on ensuring access to
patient safety technology -- such as medication management infusion
pumps with safety software -- Hospira welcomes the opportunity to
continue to work with Novation to improve patient care."
The new agreements include Hospira's general infusion medication
management technologies, such as the Plum A+™ with
Hospira MedNet™ safety software, a proven and scaleable infusion
pump system; the technologically advanced Symbiq™ infusion system
with built-in Hospira MedNet and the LifeCare PCA™ pump with
Hospira MedNet. These contracts also continue to provide Novation
with access to Hospira's I.V. solutions and associated portfolio,
including the environmentally preferable VisIV™ container. These
contracts expand upon the nearly 30-year relationship between
Hospira and the Novation group purchasing organization.
About Novation
Founded in 1998, Novation is the leading health care supply
contracting company for more than 25,000 members of VHA Inc. and
the University HealthSystem Consortium (UHC), two national health
care alliances, and 5,500 members of Provista, LLC, representing
28,000 sites. Novation provides alliance members contract and price
management and spend management services. Based in Irving, Texas, Novation develops and manages
competitive contracts with more than 600 suppliers. VHA, UHC and
Provista members used Novation contracts to purchased nearly
$37.8 billion in 2009.
About Hospira
Hospira, Inc. is a global specialty pharmaceutical and
medication delivery company dedicated to Advancing Wellness™. As
the world leader in specialty generic injectable pharmaceuticals,
Hospira offers one of the broadest portfolios of generic acute-care
and oncology injectables, as well as integrated infusion therapy
and medication management solutions. Through its products, Hospira
helps improve the safety, cost and productivity of patient care.
The company is headquartered in Lake
Forest, Ill., and has approximately 13,500 employees. Learn
more at www.hospira.com.
Private Securities Litigation Reform Act of 1995 --
A Caution Concerning Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements related to the agreements with Novation.
Hospira cautions that these forward-looking statements are subject
to risks and uncertainties that may cause actual results to differ
materially from those indicated in the forward-looking statements.
Economic, competitive, governmental, legal, technological,
regulatory and other factors that may affect Hospira's operations
and may cause actual results to be materially different from
expectations include the risks, uncertainties and factors discussed
under the headings "Risk Factors" and "Management's Discussion and
Analysis of Financial Condition and Results of Operations" in
Hospira's latest Annual Report on Form 10-K and subsequent Forms
10-Q, filed with the Securities and Exchange Commission, which are
incorporated by reference. Hospira undertakes no obligation to
release publicly any revisions to forward-looking statements as the
result of subsequent events or developments.
SOURCE Hospira, Inc.
Copyright t. 7 PR Newswire